Safest timing of pegfilgrastim administration seems to be 72 hours after chemo

the ONA take:

For the prevention of leukocytosis, the safest timing of pegfilgrastim administration based on white blood cell (WBC) count in patients receiving dose-dense anthracycline- and taxane-based regimens seems to be 72 hours following chemotherapy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.

For the study, researchers sought to determine the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy.

Researchers enrolled 41 patients and assigned them to receive pegfilgrastim 24 hours, 72 hours, or 96 hours after chemotherapy. Safety was determined by the occurrence of early and late leukocytosis and the behavior of WBCs.

Results showed that the occurrence of early leukocytosis was more common in the 24-hour cohort, while late leukocytosis occurred most frequently in the 96-hour cohort.

Researchers found that patients in the 24-hour group experienced the highest median value of WBC count 24 hours after pegfilgrastim administrated and those in the 96-hour group experienced the highest median value at day 13 in both chemotherapy cycles.

Safest timing of pegfilgrastim administration based on white blood cell count seems to be 72 hours following chemotherapy.

To evaluate the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy, three different cohorts of patients enrolled in the Gruppo Italiano Mammella (GIM) 2 study and treated at the coordinating center received pegfilgrastim 24 h (cohort A) or 72 h (cohort B) or 96 h (cohort C) after chemotherapy.